Mebiz SR

Quick links

Choose a section

Quick links to important sections

Advertisements

Mebiz SR

Advertisements
Advertisements

Overview of Mebiz SR

Property Description
Active Ingredient Mebeverine Hydrochloride
Form Sustained-Release (SR) Capsule
Pharmacological Class Antispasmodic Agent (Direct Spasmolytic)
General Purpose Relief from Abdominal Spasms and Cramping
Origin Synthetic Organic

What Type of Medicine is Mebiz SR and What is its Composition?

Mebiz SR is a prescription medicine formulated with Mebeverine Hydrochloride (INN) as its sole active ingredient. It is an established synthetic organic compound that belongs to the therapeutic class of antispasmodic agents. Its classification as a musculotropic direct spasmolytic is recognized for its focused action on the smooth muscle of the gastrointestinal tract. A key differentiation of this compound is that it is noted for having minimal systemic anticholinergic effects when compared to older or less selective spasmolytics.

Understanding the Sustained-Release (SR) Formulation

The designation "SR" confirms that Mebiz SR is specifically a modified release capsule, a specialized oral (peroral) dosage form. This formulation utilizes a polymer-based matrix to ensure the Mebeverine Hydrochloride is released slowly and consistently over a prolonged duration. This sustained action is a distinctive feature of the product, engineered to maintain a constant, effective concentration of the medicine. This makes it suitable for managing chronic abdominal cramping and discomfort.

What is the General Benefit of Mebiz SR?

The primary general benefit of Mebiz SR is to serve as a potent smooth muscle relaxant and provide relief from painful spasms in the abdomen. The drug’s direct action as a spasmolytic targets the excessive contractions in the gut. Its overall purpose is to manage the symptoms of abdominal cramping and hyperactivity by helping to restore a more regulated and quiet state to the smooth muscles of the gastrointestinal tract.

Advertisements

What side effects are possible with Mebiz SR?

Side Effects and Safety Profile for Mebiz SR (Mebeverine)

Mebeverine, the active ingredient in Mebiz SR, is generally associated with a low incidence of side effects. Most adverse reactions are rare, mild, and often affect the skin.

Adverse Reactions

The most commonly reported adverse reactions are related to hypersensitivity and allergic reactions. These typically involve the Skin and Subcutaneous Tissue system-organ class.

  • Rare Skin Reactions: This category includes mild reactions such as urticaria (hives), skin rash, inflamed or reddened skin, and pruritus (itching).
  • Serious Allergic Reactions: In very rare cases, severe systemic allergic reactions, including angioedema (swelling of the face, lips, tongue, or throat) and anaphylaxis, have been documented. These events require immediate medical evaluation.
  • Other Rare Effects: Other reactions reported in post-marketing surveillance or clinical studies include headache, dizziness, insomnia, indigestion, and constipation. The drug is noted to generally lack typical systemic anticholinergic side effects (such as dry mouth or blurred vision).

Safety Restrictions and Contraindications

The use of Mebiz SR is contraindicated in individuals with a known hypersensitivity to mebeverine or any excipients in the formulation. It is also contraindicated in patients with Paralytic Ileus.

Population Group Safety Consideration
Pregnancy Use is generally not recommended due to limited safety data; risk-benefit analysis should be conducted by a healthcare provider.
Breastfeeding Not recommended as the drug is secreted in small amounts into breast milk, and caution is advised.
Children & Adolescents Not recommended for use in children and adolescents under the age of 18 due to insufficient data to establish safety and efficacy.
Pre-existing Conditions Caution is advised in patients with severe renal or hepatic impairment, as well as those with certain hereditary sugar intolerances (e.g., lactose intolerance) due to excipient content.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Mebeverine Hydrochloride overdose indicates that manifestations are typically mild and rapidly reversible. Overdose signs primarily involve the neurological and cardiovascular systems. In general, the documented severity of overdose is considered low, with symptoms resolving quickly.

However, extremely high, massive doses have been associated with severe outcomes such as coma and bradycardia in documented cases.


Required Emergency Actions

If an overdose of Mebiz SR is suspected, official regulatory documentation states that individuals must seek immediate medical attention and go to a hospital straight away for assessment. This immediate action is required to ensure professional monitoring of the neurological and cardiovascular status.

Management and Antidote Status

Management of a Mebeverine Hydrochloride overdose focuses on symptomatic and supportive treatment. The regulatory labeling explicitly confirms that no specific antidote is known for this compound. In specific circumstances, procedures such as gastric lavage may be considered by medical professionals. No specific risk for overdose severity has been identified in elderly patients or those with existing hepatic or renal impairment based on available post-marketing data.

Advertisements

Therapeutic Uses of Mebiz SR

What Mebiz SR treats: main uses and benefits

Mebiz SR, containing mebeverine hydrochloride, is generally used in the symptom management of conditions involving episodic or fluctuating manifestations in the gastrointestinal tract. This medicine is applied across domains where additional symptomatic support is needed, particularly when patients experience symptoms of increased neurological or muscular activity within the gut.

Mebiz SR is considered relevant for the management of irritable bowel syndrome (IBS) and other conditions associated with acute or disruptive episodes. The therapeutic application is relevant for easing conditions involving inflammatory or irritative processes. This medicine helps address symptom clusters that may become intense or disruptive, including physical discomfort, abdominal pain, and cramps. It is commonly used when symptoms intensify and supportive relief is needed, providing support that helps ease the overall symptom burden.

The medicine is relevant for easing symptoms related to physical discomfort, such as abdominal pain and cramps. It is helpful in situations where symptoms create noticeable functional strain, assisting with maintaining functional stability and contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Assists with managing symptoms of physical discomfort

Regulatory References

  1. HPRA, which is the Irish medicines regulator, confirms that this drug is indicated for the management of irritable bowel syndrome
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Mebiz SR?

Population eligibility for Mebiz SR (Mebeverine Hydrochloride Sustained-Release) is strictly defined by regulatory authorities based on patient characteristics and underlying health conditions.

Regulatory Eligibility Summary

Eligibility Category Regulatory Status
Approved Population Adults (including the elderly) are an approved population for use.
Contraindicated Populations The medicine is strictly contraindicated in patients with known hypersensitivity to the active substance or excipients.
Comorbidity Restriction Contraindicated in patients with Paralytic Ileus and those with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
Pediatric Use Not recommended for children and adolescents below 18 years due to insufficient data on safety and efficacy.
Pregnancy and Lactation Not recommended during pregnancy and should not be used during breast-feeding.
Organ Impairment No specific dosage adjustment is deemed necessary for patients with hepatic or renal impairment.

Eligibility is limited by these restrictions. Use is established only within the adult population, and the drug is formally prohibited for individuals with the specific absolute contraindications listed above.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information

The regulatory documentation for Mebiz SR (Mebeverine Hydrochloride Sustained-Release) defines the product's interaction profile primarily by the absence of known or required restrictions regarding co-administration.

Category
Interacting Medicinal Products
None known. The official product information states that no interactions with other medicines are known, and it does not explicitly list any medicinal products that interact.
Interaction Mechanisms
None documented. The labels do not specify any mechanistic basis, such as effects on Cytochrome P450 enzymes or drug transporters (e.g., P-gp), for interactions with co-administered substances.
Timing Requirements
None documented. The prescribing information does not contain mandatory timing separation rules for co-administration with other medicines.
Food and Substance Interactions
Absence of interaction with Ethanol (Alcohol) demonstrated. Studies reviewed in the official regulatory documentation explicitly confirm that there is no interaction between mebeverine hydrochloride and ethanol. No documented interactions with food or specific herbal products are specified.

Interaction Classification Summary

The overall profile is characterized by a regulatory statement of minimal risk. No formal contraindicated combinations based on drug-drug interaction risk are documented in the official labeling. This structure reflects how regulatory agencies define the co-administration profile of the medicine when significant pharmacokinetic or pharmacodynamic interactions have not been found.

Advertisements

Mechanism of Action

How Mebiz SR Works: The Mechanism of Action

Mebiz SR (mebeverine) is a musculotropic antispasmodic that acts directly on the smooth muscle of the digestive tract. The mechanism focuses on modulating the overactive contractile state of these muscles, which is central to the resultant physiological activity.

Direct Modulation of Gastrointestinal Smooth Muscle

Mebeverine exerts a targeted relaxant effect directly on the gut smooth muscle, particularly in the colon. It engages mechanisms that regulate overactive or dysregulated processes within the muscle tissue, contributing to the modulation of overactive physiological responses.

Interference with Ion-Mediated Signaling Cascades

The action involves the initiation or suppression of signaling sequences that lead to downstream contraction effects. It is primarily thought to inhibit voltage-dependent calcium ( Ca^2+) channels on the muscle cell membrane, modifying this early molecular step to reduce the intracellular Ca^2+ concentration, which regulates muscle shortening.

Mechanistic Selectivity within Peripheral Pathways

The mechanism is relevant in systems where targeted pathway adjustment is required, as it acts on the muscle cell itself. The mechanism engages signaling sequences that modify local pathway activity, as it primarily acts on localized peripheral pathways.

Advertisements

Dosage and Administration Information

Administration Guidelines for Mebiz SR (Mebeverine Modified Release)

This section provides the usage instructions for the sustained-release capsule.

Key Administration Requirements

Usage Aspect Instruction (Adults)
Route & Method Oral. The capsule must be swallowed whole with a sufficient amount of water (e.g., at least 100 mL).
Preparation Do not chew, crush, or break the capsule, as this would compromise the prolonged-release mechanism.
Dose & Frequency One 200 mg sustained-release capsule twice daily (morning and evening).
Timing Relative to Meals Take the dose approximately 20 minutes before a meal (e.g., before breakfast and the evening meal).

Procedural Rules

  • Missed Dose: If one or more doses are missed, the patient should skip the missed dose(s) and continue with the next scheduled dose as prescribed. Do not take a double dose to compensate for the forgotten dose.
  • Pediatric Use: Mebeverine 200 mg modified-release capsules are not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy. The duration of use is generally not limited but should be determined by a physician.

The administration requirements establish a precise protocol: the sustained-release format dictates that the capsule must remain intact when swallowed, while the twice-daily timing 20 minutes before a meal standardizes the dose's delivery relative to the digestive cycle. Adherence to these steps, including the rule for handling missed doses, ensures the drug is used according to its specifications.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Mebiz SR

Clinical Trials and Evidence for Irritable Bowel Syndrome (IBS)

Research has been studied for its application in Irritable Bowel Syndrome (IBS). This involves Randomized Controlled Trials (RCTs) and meta-analyses that combine results from multiple studies. These trials primarily examine outcomes related to physical discomfort, specifically the intensity of abdominal pain and cramping. Researchers also monitored patient-reported outcomes describing perceived discomfort related to bloating and changes in bowel habits in adult populations.

During the study periods, some trials reported measurements of symptom changes in the observed populations. Findings describe patterns observed in patients regarding overall clinical status. However, evidence quality varies across studies, and some systematic reviews pooling the trial data findings were mixed regarding the consistency of these observed patterns. This inconsistency contributes to the classification of the overall evidence as Moderate.

Comparing Study Outcomes: Placebo and Symptom Relief

Many trials research examined mebeverine's effect against a placebo (an inactive treatment) to distinguish between the medicine’s observed effect and general symptom evolution. Studies also explored how the medicine compared to other types of treatment. The findings from different meta-analyses regarding these comparisons have shown inconsistency, meaning that while some studies describe patterns of reported change, others do not show the same observations when combining data.

Understanding Long-Term Research and Follow-up Duration

The primary evidence base comes from core RCTs where follow-up durations were limited, typically lasting only a few weeks to a few months. This research exploring short-term symptom changes provides context regarding episodes where symptoms become more noticeable. However, long-term effects are not fully established, and there is limited information for long-term outcomes or the durability of the observed symptom patterns over a sustained period of time.

Consistency and Gaps in the Research Record

The research landscape is classified as having a Moderate evidence level due to the nature of the studies, which is tempered by several limitations. A major limitation is the noted significant heterogeneity in the studies, meaning that different trials used different methods to measure the same outcomes. Furthermore, sample sizes were modest in some of the core meta-analyses. Due to these factors, certainty remains low in some areas of the research, and the findings describe group patterns, not personal outcomes, and do not determine whether an individual will respond similarly.

Key Studies & References Mebeverine Summary of Product Characteristics (SmPC) / Regulatory Licence for Oral Capsule

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Mebiz SR (FAQ)


Q: Is Mebiz SR the same kind of medicine as other drugs used for similar issues?

Mebiz SR belongs to a specific therapeutic class called musculotropic antispasmodics. These medicines work by having a direct relaxing effect on the smooth muscles of the digestive tract, helping to modulate excessive contractions in the gut.


Q: Is Mebiz SR used for anything besides its main approved use?

Regulatory documents describe the use of Mebiz SR for the symptomatic relief of Irritable Bowel Syndrome (IBS). It is also used for the management of symptoms associated with other conditions that cause intestinal spasms, such as spastic colitis or chronic irritable colon.


Q: What happens if you stop taking Mebiz SR suddenly?

Official guidance describes that the dosage is often adjusted or discontinued by a professional when symptoms improve. The official product information does not specify a known syndrome or negative effects related to suddenly discontinuing the medicine.


Q: Do older adults need to be monitored more closely while taking Mebiz SR?

Official information indicates that no specific risks for older patients have been identified from available post-marketing data. Therefore, no specific change in dosage is generally deemed necessary for the elderly population.


Q: Can Mebiz SR cause mood changes or unusual dreams?

The regulatory safety profile lists adverse effects related to the central nervous system, such as headache, dizziness, and difficulty sleeping (insomnia). Specific terms like 'mood changes' or 'unusual dreams' are not commonly or consistently listed in the official documents.


Q: What should I do if I feel dizzy or lightheaded after taking Mebiz SR?

Dizziness is listed in the regulatory documents as a possible side effect. Official documents indicate that if dizziness occurs, avoidance of activities that require alertness, such as driving or operating heavy machinery, is a standard measure.


Q: What are the most commonly reported side effects of Mebiz SR in studies?

The most commonly reported adverse reactions are generally linked to hypersensitivity and allergic reactions. These typically affect the skin and may appear as an itchy rash, urticaria (hives), or reddened skin.


Q: How often do people experience severe side effects from Mebiz SR?

Official product information states that most adverse reactions are mild and short-lived. Severe systemic allergic reactions, such as the swelling of the face, lips, or throat (angioedema), are documented as rare or very rare events.


Q: Do studies suggest that Mebiz SR is effective for all patients?

The research findings describe patterns observed in groups of patients during clinical trials. Official documents clarify that these group findings do not determine whether a specific individual patient will experience the same level of symptom relief.


Q: Is Mebiz SR approved in countries outside the US?

Yes, mebeverine is a globally established compound. Official regulatory documentation for Mebiz SR is available in jurisdictions across Europe, the United Kingdom, and other regions internationally.


Q: Are there any common supplements that interact with Mebiz SR?

While regulatory documents state that no known interactions with other prescription medicines are documented, some authoritative sources advise caution with herbal remedies and supplements. This is because these products are often not formally studied in combination with the drug.


Q: Does taking Mebiz SR affect sleep?

Insomnia, which is difficulty sleeping, has been reported in regulatory documents as an occasional adverse effect of the medicine.


Q: Can Mebiz SR be taken with ibuprofen or aspirin?

Authoritative health sources describe that co-administration with common, everyday pain relievers such as paracetamol and ibuprofen is generally not restricted by official interaction warnings.


Q: Will Mebiz SR show up on a drug screening test?

Official product information notes that in rare instances, mebeverine has the potential to cause a false positive result for amphetamines on a urine drug-screening test.


Q: Is there a generic version of Mebiz SR available?

Yes, mebeverine hydrochloride, the active ingredient, is a generic compound that is widely available internationally under multiple different brand and generic names.


Q: What are the typical reasons a person would be told they cannot use Mebiz SR?

In addition to absolute restrictions (contraindications), regulatory information lists a range of symptoms and conditions, such as fever or unexplained weight loss, that are noted as reasons for caution before use.


Q: Can Mebiz SR cause skin reactions or rashes?

Yes, common reported adverse reactions include skin issues such as a mild itchy rash, hives (urticaria), and reddened skin. These reactions are typically related to hypersensitivity to the drug.


Q: Is Mebiz SR used to treat anxiety or stress?

Mebiz SR is officially classified as an antispasmodic medicine, and its approved purpose is for the management of abdominal symptoms like cramps and pain. It is not approved for the treatment of anxiety or stress.


Q: Are there specific laboratory tests required while on Mebiz SR?

Official prescribing information does not describe mandatory laboratory tests for routine use in all patients. However, caution is advised in patients with severe kidney or liver impairment, according to official prescribing information.

Advertisements

How should Mebiz SR be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions and Protection

The regulatory labeling for Mebiz SR (mebeverine) specifies strict conditions to maintain its quality and efficacy. The medication must be stored in a cool and dry place, generally below 30 C (or not exceeding 30 C). It is mandatory to keep the product in its original package to ensure protection from moisture and light. To prevent accidental ingestion, the medication must be stored out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Mebiz SR must not be thrown away via household trash or wastewater, as this can pose environmental risks. The official guidance requires patients to consult a pharmacist about local drug take-back programs or other special methods for discarding medicines. Proper disposal is necessary to prevent consumption by pets, children, or others and to minimize the product's environmental impact.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mebiz SR found in:

A-Z Index: